Testing dupilumab for severe itching after burn injuries
Treatments studied
Part of Skin clinical trials.
This trial tests if dupilumab (Dupixent) can help adults with long-lasting, severe itching from healed burn scars. It is for people whose itching has not improved with standard treatments like antihistamines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have a healed burn scar that needed skin grafting, and you still have severe itching.
- Your itching has not been helped by standard medicines (like antihistamines) for at least 4 weeks.
- It has been at least 4 weeks since your last skin graft surgery.
- You are not currently taking dupilumab, steroids, or laser therapy for itching.
- You do not have other skin conditions, active cancer, serious kidney or liver disease, or are pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
This early trial tests whether dupilumab can reduce itching in people with certain inherited (genetic) inflammatory skin conditions. It may help by calming skin inflammation that causes ongoing itch and sleep problems.
This study tests whether the medication dupilumab can safely reduce itching and skin bumps in children aged 6 months to under 18 years who have prurigo nodularis, a skin condition that causes intense itching and nodules. Participation involves taking the study drug and tracking itch daily.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
This trial studies whether dupilumab can improve daily body clock (circadian function), sleep, and itching in children with moderate-to-severe eczema that isn’t well controlled by creams. It may help kids who are having significant sleep trouble and ongoing itch.
This study checks blood antibodies (BP180 and BP230) in people who develop long-lasting itching after starting immune therapy for cancer. It may help doctors understand why the itching happens and how it relates to autoimmune skin conditions.
Hear when a new Pruritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.